Agenus Inc. (AGEN)
$
5.92
+0.74 (12.50%)
Key metrics
Financial statements
Free cash flow per share
-5.9577
Market cap
142 Million
Price to sales ratio
1.4270
Debt to equity
-0.8695
Current ratio
0.1111
Income quality
0.7407
Average inventory
0
ROE
1.0634
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
Agenus Inc., a clinical-stage immuno-oncology company operating in the United States and internationally, is focused on discovering and developing innovative immuno-oncology products. The company's operating income ratio is -1.16 indicating the company's operational profitability margin. Additionally, the gross profit ratio is -0.51 reflecting the efficiency of the company's production and sales operations. Agenus Inc. leverages its Retrocyte Display, an advanced antibody expression platform, for identifying fully human and humanized monoclonal antibodies. The organization also develops various vaccine programs, including the Prophage vaccine candidate and QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvant. Its product pipeline features several promising candidates, such as Balstilimab, an anti-PD-1 antagonist that has completed a Phase II clinical trial for second line cervical cancer, AGEN1181, an anti-CTLA-4 monospecific antibody currently in Phase 1/2 clinical trial, and AGEN2373, an anti-CD137 monospecific antibody in Phase 1 clinical trial. Other notable developments include AGEN1423, a tumor microenvironment conditioning anti-CD73/TGFß TRAP bi-functional antibody that has finished its Phase 1 clinical trial, and AGEN1777, an anti-TIGIT bispecific antibody. Furthermore, AGEN1327 is a human monoclonal antibody, while INCAGN1876, INCAGN1949, INCAGN2390, and INCAGN2385 are specialized anti-GITR, anti-OX40, anti-TIM-3, and anti-LAG-3 monoclonal antibodies, respectively. The company also has ARDS-targeting AGENT 797 in Phase 1 clinical trials, and AGEN1884, a first-generation anti-CTLA-4 antibody. Agenus collaborates with Incyte Corporation, Merck Sharpe & Dohme, Recepta Biopharma SA, and Gilead Sciences, Inc. Founded in 1994 and headquartered in Lexington, Massachusetts, Agenus Inc. was formerly known as Antigenics Inc. and rebranded in January 2011. The company reported depreciation and amortization expenses of $13,343,000.00 reflecting the wear and tear of its assets. The EBITDA is -$101,302,000.00 a key indicator of the company's operational profitability. The financial data pertains to the fiscal year 2024. As a small-cap player with a market capitalization of $162,307,456.00 Agenus controls a pivotal role in the Biotechnology industry, making significant contributions to the overall market landscape. The stock is affordable at $5.92 making it suitable for budget-conscious investors. However, the stock has a low average trading volume of 1,229,131.00 indicating lower market activity. The company belongs to the Healthcare sector, driving innovation and growth within the evolving landscape of immuno-oncology.
Investing in Agenus Inc. (AGEN) depends on multiple factors, including revenue growth, profit margins, debt-to-equity ratio, earnings per share, and return on equity. Analysts have rated it as C, with a Bullish outlook. Always conduct your own research before investing.
Analysts predict Agenus Inc. stock to fluctuate between $1.38 (low) and $18.74 (high) in the next 365 days, reflecting market expectations and potential volatility.
As of 2025-07-10, Agenus Inc.'s market cap is $162,307,456, based on 27,416,800 outstanding shares.
Compared to Eli Lilly & Co., Agenus Inc. has a Lower Market-Cap, indicating a difference in performance.
To buy Agenus Inc. (AGEN) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for AGEN. Place an order (Market, Limit, etc.).
The best time to invest depends on market trends and technical indicators, which show a Bullish trend based on economic conditions and company performance.
Agenus Inc.'s last stock split was 1:20 on 2024-04-12.
Revenue: $103,463,000 | EPS: -$10.59 | Growth: -22.98%.
Visit https://www.agenusbio.com/investor-relations for detailed financial reports.
You can explore historical data from here
All-time high: $135.80 (2021-08-30) | All-time low: $1.38 (2025-04-07).
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News
zacks.com
After reaching an important support level, Agenus Inc. (AGEN) could be a good stock pick from a technical perspective. AGEN recently experienced a "golden cross" event, which saw its 50-day simple moving average breaking out above its 200-day simple moving average.
businesswire.com
LEXINGTON, Mass. & SAN FRANCISCO--(BUSINESS WIRE)--Agenus Inc. (Nasdaq: AGEN) a leader in immuno-oncology innovation and Noetik, a leader in AI-driven spatial and multimodal biology, today announced a research collaboration to develop predictive biomarkers of response to Agenus' lead clinical stage immuno-oncology (IO) combination, botensilimab (BOT, multifunctional Fc-enhanced anti-CTLA-4) and balstilimab (BAL, anti-PD-1). The collaboration harnesses Noetik's proprietary virtual cell foundatio.
businesswire.com
LEXINGTON, Mass.--(BUSINESS WIRE)--Agenus Inc. (“Agenus”) (NASDAQ: AGEN), a leader in immuno-oncology innovation, today announced that its Annual Shareholders Meeting will begin at 10:30 a.m. ET on June 17, 2025, and will be conducted in a virtual format only. Registration for attendees will start at 10:15 a.m. ET. To participate in the Annual Shareholders Meeting, shareholders should visit www.virtualshareholdermeeting.com/AGEN2025 and enter the 16-digit control number found in their proxy mat.
benzinga.com
On Tuesday, Zydus Lifesciences Ltd. announced its entry into the global biologics contract development and manufacturing organization (CDMO) business through its plan to acquire Agenus Inc.'s AGEN U.S.-based biologics CMC facilities.
zacks.com
The mean of analysts' price targets for Agenus (AGEN) points to a 26.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
businesswire.com
LEXINGTON, Mass.--(BUSINESS WIRE)--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology, today presented new translational data at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting. The study demonstrates that botensilimab-based therapy induces a robust and persistent T cell immune response in microsatellite stable (MSS), or mismatch repair proficient (pMMR), metastatic colorectal cancer (mCRC)—a tumor type traditionally resistant to immunotherapy and representing approxim.
seekingalpha.com
I remain cautiously optimistic about Agenus, driven by BOT/BAL's strong clinical data and cost-reduction efforts, but maintain a speculative 2/5 conviction rating. The BOT/BAL program shows promising efficacy in MSS colorectal cancer, potentially resetting the standard of care and offering a significant commercial opportunity. Agenus's restructuring, asset monetization, and cost cuts aim to extend the runway and avoid near-term dilution, but financial risks and execution remain key concerns.
zacks.com
If you are looking for stocks that have gained strong momentum recently but are still trading at reasonable prices, Agenus (AGEN) could be a great choice. It is one of the several stocks that passed through our 'Fast-Paced Momentum at a Bargain' screen.
businesswire.com
LEXINGTON, Mass.--(BUSINESS WIRE)--Agenus Inc. (“Agenus” or the Company”) (NASDAQ: AGEN), a leader in immuno-oncology, today announced new data from its ongoing Phase 1 trial evaluating botensilimab and balstilimab (BOT/BAL) in patients with microsatellite stable (MSS) metastatic colorectal cancer (mCRC) at the 2025 European Society for Medical Oncology (ESMO) Gastrointestinal Cancers Congress in Barcelona, Spain. A poster presentation will feature updated findings from an expanded cohort of 12.
seekingalpha.com
Agenus Inc. (NASDAQ:AGEN ) Q1 2025 Earnings Conference Call May 12, 2025 8:30 AM ET Company Participants Zack Armen - Head of Investor Relations Garo Armen - Chairman and CEO Steven O'Day - Chief Medical Officer Robin Taylor - Chief Commercial Officer Richard Goldberg - Chief Development Officer Christine Klaskin - VP Finance and Principal Financial and Accounting Officer Conference Call Participants Emily Bodnar - H.C. Wainwright Mayank Mamtani - B.
See all news